E
ERAS
Erasca, Inc.
17.81
+1.21+7.29%After Hours: 17.98 +0.17 +0.95%19:56 04/02 EDT
OPEN/PREV CLOSE16.95/17.12
TODAY RANGE16.12-17.07
VOL6.36K
MARKET CAP5.30B
52 WEEK RANGE1.010-18.20
AVG VOL (3M)5.79M
% TURNOVER0%
TURNOVER0
P/E (TTM)-38.8345
% RANGE--
EPS(TTM)-0.4393
P/E(FORWARD)-37.0870
P/B14.91
BVPS1.144
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP4.35B
SHARES OUTSTANDING310.80M
NEXT EARNINGS05/11-05/15
FREE FLOAT254.93M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·8h ago
Assessing Erasca (ERAS) Valuation After ERAS-0015 Trial Progress And Supportive FDA And Analyst Updates
NASDAQ·5d ago
ERAS Crosses Above Average Analyst Target
TipRanks·5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Benzinga·03/31 13:57
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
TipRanks·03/24 10:18
Bank of America Securities Reaffirms Their Sell Rating on Erasca (ERAS)
Seeking Alpha·03/23 18:47
Top performing mid-cap stocks YTD as volatility hits markets
Simply Wall St·03/22 02:05
A Look At Erasca (ERAS) Valuation After Its Strong Recent Share Price Rally
Simply Wall St·03/20 16:14
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors
Dow Jones·03/18 15:55
Erasca Price Target Raised to $25.00/Share From $24.00 by JP Morgan
Dow Jones·03/18 15:55
Erasca Is Maintained at Overweight by JP Morgan
Benzinga·03/18 15:46
JP Morgan Maintains Overweight on Erasca, Raises Price Target to $25
TipRanks·03/18 11:28
Erasca price target raised to $25 from $24 at JPMorgan
Same Industry
Name/Symbol
Change%
Price